Alpha-1 antitrypsin deficiency
RecruitingStudy on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency
Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency
- Disease:Alpha-1 antitrypsin deficiency
- Substances:Human ALPHA1-PROTEINASE inhibitor
Germany- Participants:18–64 years · 65+ years
- Substances:Human ALPHA1-PROTEINASE inhibitor
- Sponsor:Grifols S.A.











